Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Recipharm Inks Covid-19 Vax Pact with Moderna | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Recipharm Inks Covid-19 Vax Pact with Moderna

Signs of letter of intent for aseptic fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate (mRNA-1273).

By: Contract Pharma

Contract Pharma Staff

Recipharm, a contract development and manufacturing organization (CDMO), has signed a letter of intent with Moderna, a U.S.-based biotech, to formulate, fill and finish mRNA-1273, Moderna’s COVID-19 vaccine candidate. The activity will be performed in Recipharm’s drug product manufacturing facility located in Monts, France. Recipharm has reserved capacity to support the anticipated demand for the vaccine and is already in the process of recruiting additional staff and making certain investments to enable technology transfer and scale-up to begin imminently.
 
“We are delighted to be working with Moderna on this vital project in order to support the fight against COVID-19,” said Thomas Eldered, chief executive officer, Recipharm. “Our operations in France are ideally suited to perform this work by combining our technical and operational knowhow to deliver high-quality pharmaceutical manufacture of biologics with a challenging timeline. We anticipate that the final agreement will be finalized during December.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics